{"id":"NCT03198507","sponsor":"RedHill Biopharma Limited","briefTitle":"ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator","officialTitle":"A Randomized Double Blind Active Comparator Controlled Phase III Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-18","primaryCompletion":"2018-10-24","completion":"2018-12-13","firstPosted":"2017-06-26","resultsPosted":"2020-03-16","lastUpdate":"2020-03-16"},"enrollment":455,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Helicobacter Pylori Infection","Dyspepsia"],"interventions":[{"type":"DRUG","name":"RHB-105","otherNames":["Amoxicillin, Omeprazole and Rifabutin"]},{"type":"DRUG","name":"Active Comparator","otherNames":["Amoxicillin and Omeprazole"]}],"arms":[{"label":"RHB-105","type":"EXPERIMENTAL"},{"label":"Active Comparator","type":"ACTIVE_COMPARATOR"}],"summary":"The \"test and treat\" strategy for treating dyspeptic patients who are H. pylori positive is rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a new triple therapy to treat H. pylori infection in dyspeptic patients against an active comparator.","primaryOutcome":{"measure":"Number of Participants With Eradication of H. Pylori","timeFrame":"43-71 days after initiation of treatment","effectByArm":[{"arm":"RHB-105","deltaMin":191,"sd":null},{"arm":"Active Comparator","deltaMin":131,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":55,"countries":["United States"]},"refs":{"pmids":["34862940","32365359"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":228},"commonTop":["Diarrhoea","Headache","Nausea"]}}